Literature DB >> 25034292

Non-alcoholic fatty liver disease: diagnosis and investigation.

Fabio Nascimbeni1, Paola Loria, Vlad Ratziu.   

Abstract

Given the worldwide increase in obesity and diabetes, non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease. NAFLD is associated with increased hepatic and extrahepatic morbidity and mortality, mainly related to non-alcoholic steatohepatitis with fibrosis. An early diagnosis in the high-risk population with features of insulin resistance and a proper identification of those patients with progressive liver disease are needed. Practicing physicians dealing with NAFLD should be aware of and should carefully evaluate the extended spectrum of NAFLD-related extrahepatic diseases, which significantly affects liver- and non-liver-related prognosis. This clinical practice-oriented article reviews the diagnostic methods and staging strategies for NAFLD and proposes an investigational algorithm for a global evaluation of NAFLD patients.

Entities:  

Mesh:

Year:  2014        PMID: 25034292     DOI: 10.1159/000360510

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  3 in total

1.  Nimbolide attenuate the lipid accumulation, oxidative stress and antioxidant in primary hepatocytes.

Authors:  Ghedeir M Alshammari; Aristatile Balakrishnan; Thirunavukkarasu Chinnasamy
Journal:  Mol Biol Rep       Date:  2017-11-28       Impact factor: 2.316

Review 2.  Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection--Liver: The "Musketeer" in the Spotlight.

Authors:  Stefano Ballestri; Fabio Nascimbeni; Dante Romagnoli; Enrica Baldelli; Giovanni Targher; Amedeo Lonardo
Journal:  Int J Mol Sci       Date:  2016-03-09       Impact factor: 5.923

Review 3.  Nonalcoholic fatty liver disease: Evolving paradigms.

Authors:  Amedeo Lonardo; Fabio Nascimbeni; Mauro Maurantonio; Alessandra Marrazzo; Luca Rinaldi; Luigi Elio Adinolfi
Journal:  World J Gastroenterol       Date:  2017-09-28       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.